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Abstract
Drug-induced nephrolithiasis is a rare condition in children. The involved drugs may be divided into two different categories 
according to the mechanism involved in calculi formation. The first one includes poorly soluble drugs that favor the crystal-
lization and calculi formation. The second category includes drugs that enhance calculi formation through their metabolic 
effects. The diagnosis of these specific calculi depends on a detailed medical history, associated comorbidities and the 
patient’s history of drug consumption. There are several risk factors associated with drug-induced stones, such as high dose 
of consumed drugs and long duration of treatment. Moreover, there are some specific risk factors, including urinary pH and 
the amount of fluid consumed by children. There are limited data regarding pediatric lithogenic drugs, and hence, our aim 
was to perform a comprehensive review of the literature to summarize these drugs and identify the possible mechanisms 
involved in calculi formation and discuss the management and preventive measures for these calculi.
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Key Points 
Drug-induced urinary stone formation in the pediatric 
population is rare.
Knowledge of these stones is of great clinical importance 
as they may be missed, resulting in major health conse-
quences.
Ceftriaxone, furosemide and topiramate are the most 
common drugs inducing stone formation in children.
1 Introduction
Urolithiasis is a common urological disorder with a higher 
prevalence in adults than in the pediatric population; how-
ever, pediatric urolithiasis is an evolving field of interest 
due to the dramatic increase in its incidence (up to five-
fold) over the past 2 decades, with the subsequent increase 
in its associated morbidity and management costs [1, 2]. 
The Rochester Epidemiology Project database showed that 
there was a 4% annual increase in pediatric kidney stones 
from 1984 to 2008, which was more pronounced in older 
children, between 12 and 17 years old [3]. Moreover, a popu-
lation-based study between 1997 and 2012 in South Carolina 
reported a 16% annual increase in the incidence of renal 
stones, particularly in young female patients between 10 and 
24 years old [4]. Furthermore, pediatric nephrolithiasis is 
also associated with a high risk of recurrence, reaching up to 
50% within 3 years from the first episode of nephrolithiasis 
[5]. The reason behind this increased prevalence remains 
elusive because of the lack of studies and may be multifacto-
rial. The increased use and sensitivity of radiological studies 
(like computed tomography) may be associated with more 
diagnoses of stone disease in children [3, 6]. Furthermore, 
the metabolic abnormalities resulting from the increasing 
rates of pediatric obesity over the last few decades may play 
a role [7]; however, supporting evidence is not strong in the 
pediatric population [3]. Unhealthy diets among children 
and adolescents are another factor that may contribute to 
the rising incidence of pediatric urolithiasis, for example, 
reduced water intake, increase sodium consumption, and 
sugary drinks. These unhealthy dietary habits may result in 
urine supersaturation with calcium, oxalate and phosphate 
and predispose individuals to urinary stone formation [8].
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The rising incidence of pediatric nephrolithiasis has also 
been associated with a shift in its etiology from infectious to 
metabolic factors [2, 9, 10]. This etiological shift was con-
firmed by the higher number of urine metabolic abnormali-
ties in children ≤ 10 years old compared to those > 10 years 
old [11]. In some cases, nephrolithiasis was linked to the use 
of specific drugs or medications. Drug-induced nephrolithi-
asis accounts for 1–2% of all kidney stones [12]. There are 
scarce data about pediatric lithogenic drugs in the literature 
in this setting; we aimed to perform a review to analyze the 
available literature data about these drugs.
2  Pediatrics Age Definition
The pediatric age limit in this review was determined based 
on the American Academy of Pediatrics’ statement. This 
statement defines pediatric patients as any patient starting 
from birth to 21 years old [13].
3  Methodology
In this narrative literature review, an extensive search of the 
Medline database was performed by two of our authors (A.E. 
and A.Z.) to identify the articles discussing the lithogenic 
effect of commonly used drugs in the pediatric population. 
We included only articles published in English, without any 
time restrictions. A combination of the following keywords 
was used: “pediatric,” “children,” “child,” “calculi,” “uri-
nary calculi,” “nephrolithiasis,” “urolithiasis,” “stones,” 
“calculus,” “medications,” “drugs,” “ceftriaxone,” “topira-
mate,” “allopurinol,” “silica,” “silicate,” “furosemide,” “zon-
isamide,” “vitamins,” “antibacterial,” “diuretics,” “antiepi-
leptic,” and “sulphonamides.” Furthermore, a manual search 
of the references of the identified articles was performed to 
identify all reports of interest.
4  Drug‑Induced Nephrolithiasis 
Mechanisms
Generally, stone formation starts with the supersaturation of 
specific pathological or physiological ions in the urine, result-
ing in the formation of a nidus that represents the nucleus for 
the urolithiasis. This is followed by crystallization or forma-
tion of more crystals in the urine that allows the aggregation 
and growth of the stone. Urine supersaturation can be affected 
by several factors, including the total urine volume, stone-
forming ions concentration, concentration of the inhibitors 
and promoters of crystallization, and the urinary pH [14].
Drug-induced nephrolithiasis can be classified based on 
its pathophysiology into (1) drug-containing nephrolithiasis, 
where the urine becomes supersaturated with the drug itself 
or one of its metabolites, and thus the drug or its metabolites 
are a component of the stone; and (2) metabolically drug-
induced nephrolithiasis, where the drug or its metabolites 
cause metabolic changes in the urine contributing to stone 
formation, but the drug is not a component of the stone. This 
type of drug-induced renal stone is more challenging to diag-
nose, as these stones have a similar composition to common 
calculi, and diagnosis is mainly based on careful history tak-
ing [12]. Table 1 shows a summary of the pathophysiology 
and treatment options for different lithogenic drugs.
5  Lithogenic Drugs
5.1  Drug‑Containing Nephrolithiasis
Table 2 shows a summary of the published reports on drug-
containing nephrolithiasis.
5.1.1  Sulphonamides
Sulphonamides are a group of compounds that have been 
recognized for their antimicrobial effect since the late 1930s 
[15]; however, their use has decreased overtime due to the 
associated side effects and the production of new antibac-
terial drugs [16]. Lately, they have emerged again for the 
treatment of toxoplasmosis, especially in patients suffering 
from human immunodeficiency virus (HIV)/acquired immu-
nodeficiency syndrome (AIDS) [16].
Sulphonamide-induced urolithiasis has been documented 
in the literature starting as early as 1939 [17]. Since then, 
multiple reports have been published [15, 18, 19]; however, 
the lithogenic effect of these compounds in the pediatric 
population has been demonstrated only in five patients [16, 
20–22]. This may be explained by the scarcity of toxoplas-
mosis and HIV/AIDS in children [16]. Sulphadiazine was 
the most commonly reported drug in this group, and it was 
associated with crystalluria in two patients [20, 22] and 
bilateral urolithiasis in another two patients [16]. On the 
other hand, Erturk et al. [21] reported drug-induced uro-
lithiasis in a 19-year-old girl while using sulfasalazine for 
treatment of juvenile rheumatoid arthritis. It is notewor-
thy to mention that the urine analysis of the two patients 
with crystalluria showed sulphonamide crystals [20, 22]; 
in addition, in patients with stones, stone analysis showed a 
sulphonamide component in the stone, supporting the litho-
genic effect of sulphonamides [16, 21].
5.1.1.1 Pathophysiology Sulphonamides are absorbed 
immediately after any route of administration, then part 
of the drug goes through acetylation in the liver, followed 
by its excretion (free and acetylated) by the kidney [15]. 
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They are capable of producing renal damage through differ-
ent mechanisms, including crystallization and obstruction 
or to a lesser extent through interstitial nephritis and toxic 
acute tubular necrosis [16]. The process of crystallization 
is related to the urinary pH and the solubility of sulphona-
mides. Sulphadiazine and its acetyl derivative are character-
ized by their relatively low solubility in acidic urine, raising 
the risk of precipitation and urolithiasis [23]. Several risk 
factors (large doses, acidic urine, dehydration, and underly-
ing tubular diseases) may favor sulphonamide urolithiasis in 
the pediatric population [16]. Sulphonamide-induced stones 
usually show the presence of acetylated derivatives (N-ace-
tylsulfadiazine or acetylsulfapyridine) in their composition 
[16, 21].
5.1.1.2 Treatment and Prevention This lithogenic effect of 
sulphonamides can be reduced by using sodium bicarbonate 
to alkalinize urine to maintain urinary pH > 7.5, ensur-
ing proper hydration, and using the minimal effective dose 
[16]. The management of this type of stone usually includes 
discontinuation or replacement of sulphonamides, proper 
hydration, and urine alkalization; however, in the pediatric 
population, stenting, shockwave lithotripsy (SWL) and ure-
thral dilatation have been indicated [16, 20–22].
5.1.2  Ceftriaxone
Ceftriaxone is a third-generation cephalosporin and is char-
acterized by its broad spectrum, high safety profile and 
long plasma half-life, rendering it among the commonly 
used antibacterial drugs during the childhood period for 
the treatment of different bacterial infections [24]. Ceftri-
axone has been known for its biliary side effects, includ-
ing biliary sludge and pseudolithiasis since the late 1980s 
[25]. In 1988, Schaad et al. [26] reported the first case of 
ceftriaxone-induced nephrolithiasis in one child out of 37 
children. Soon after that, several authors reported crystallu-
ria [27, 28], hypercalciuria [29, 30] and urolithiasis [31–45] 
in children following ceftriaxone use. It is considered the 
most common lithogenic antibacterial drug in the pediat-
ric population, with an incidence ranging from 0.6% [45] 
to 8.3% [31]. A systematic review of 161 Chinese patients 
analyzing the age distribution of patients with ceftriaxone-
induced urolithiasis showed that 21.1%, 19.3%, and 19.3% 
of those patients were < 3, 3–6, and 7–17 years old, respec-
tively (overall 59.7% for the pediatric population from 0 to 
17 years old), compared to 40.3% in the adult population, 
demonstrating a predominance of this side effect in pediatric 
patients [46].
5.1.2.1 Pathophysiology Ceftriaxone is mainly excreted in 
the urine (33–67%), and the remaining parts are excreted 

















































































































































































































































































































































































































































































Lithogenic Drugs in Pediatrics
terized by a plasma half-life of 5.8–8.7 h, plasma clearance 
of 0.58–1.45 L/h, and renal clearance of 0.32–0.73 L/h [31]. 
Being an anion, it is capable of forming an insoluble salt 
with calcium in a 1:1 molar ratio, resulting in precipitation 
of this salt once its solubility is exceeded. This may be the 
underlying mechanism for its biliary side effects [29]; how-
ever, the mechanism of ceftriaxone-induced nephrolithiasis 
is not yet completely understood [31].
In this setting, several authors have tried to investigate the 
pathophysiological mechanism for ceftriaxone-associated 
renal side effects [24, 46]. Zhang et al. [46] demonstrated in 
their animal study that the rats that were administered cef-
triaxone and calcium showed a significantly lower volume 
of 24-h urine, with a significant increase in serum creatinine 
and blood urea nitrogen levels, suggesting that calcium chlo-
ride is important for stone formation. This is in contrast to 
Avci et al. [33], who reported unchanged calcium excretion 
in children treated with ceftriaxone. Moreover, Chatchen 
et al. [24] microscopically examined a Madin-Darby canine 
model (a model of distal renal tubular cells) in the presence 
and absence of ceftriaxone crystals for 48 h, demonstrating 
that heat stress response and heat shock protein 70 play an 
important role in the process of crystalline nephropathy and 
post-ceftriaxone acute renal injury.
Several risk factors for ceftriaxone-induced nephrolithi-
asis have been discussed in the literature, including a posi-
tive family history of stones, high dosage (> 100 mg/kg/
day), rapid infusion rates (< 30 min), and dehydration [27]. 
Furthermore, Cong et al. [47] used an in vitro crystallization 
model to illustrate that ceftriaxone-induced crystallization 
was significantly decreased by lowering the urinary pH or 
increasing the urinary citrate level. In this setting, the dos-
age of ceftriaxone ranged from 50 to 100 mg/kg/day in the 
included studies, while the ceftriaxone-induced stone devel-
oped after 2 [28] to 16 [41] days. In the current review, only 
two studies reported the urine pH (7.32 and 5–6.5) after 
ceftriaxone treatment [35, 37] and four studies reported the 
calcium/creatinine ratio, ranging from 0.098–0.356 [29, 31, 
33, 42].
Ceftriaxone-induced stones usually show ceftriaxone as 
their main component, and they are normally radiolucent; 
thus they are not diagnosed with plain X-rays, unless other 
calcium salts are found in their composition. They are char-
acterized by their small size, loose texture and sand-like 
appearance, and they are usually asymptomatic and discov-
ered on ultrasound examination [35]. However, in the current 
review, only six studies (30%) reported the stone analysis 
showing the presence of ceftriaxone and thus establishing 
the relationship between ceftriaxone administration and uro-
lithiasis or crystalluria [32, 34, 35, 37, 39, 41].
5.1.2.2 Prevention and Treatment According to the study 
of Zhang et  al. [46], citrate is capable of preventing the 
urinary biochemical changes resulting from ceftriaxone 
use and thus reducing its lithogenic effect. Ceftriaxone-
induced nephrolithiasis and biliary pseudolithiasis are usu-
ally reversible and can disappear after 5–21 and 2–63 days, 
respectively [27, 44]. The current review demonstrated that 
most of the cases were treated by replacement or discontinu-
ation of ceftriaxone and hydration (Table 2); however, some 
patients required surgical intervention like double J (DJ) 
stenting and ureteroscopy, and only one patient required an 
open surgical intervention, due to failure of DJ stenting and 
the development of deep and quick breathing with arrhyth-
mia [35].
5.1.3  Triamterene
Triamterene is a potassium-sparing diuretic that may cause 
nephrolithiasis in the adult population, due to its high uri-
nary excretion and low urinary solubility [12]. Only one 
case report was found about this diuretic in the pediatric 
population, where a 21-year-old female patient was using 
it for a duration of 18 months to control her stone disease. 
The patient passed a ureteral calculus that was analyzed and 
showed 70% of the stone composition was made up of tri-
amterene and triamterene metabolites. Triamterene stones 
are usually small and golden-mustard in color [48]. Fur-
thermore, the main risk factors associated with triamterene-
induced stones are low urinary pH and high drug doses [12].
5.1.4  Felbamate
Felbamate (FBM) is a lipophilic drug that is characterized 
by low water solubility. It is mainly excreted through the 
kidney (90%), with approximately 43–63% of it excreted 
unchanged [49]. FBM has a high safety profile, and was 
Food and Drug Administration (FDA) approved in 1993 
for the treatment of refractory seizures and Lennox-Gastaut 
syndrome. The recommended dosages are 3600 mg/day for 
adults and 45 mg/kg/day for children. Most of the FBM-
associated side effects occur with a relatively high dose of 
FBM [50]. Only three reports were found in the literature 
about the relation between FBM and urolithiasis in the pedi-
atric population [49–51]. The pathophysiology of FBM-
induced urinary stones is still vague; however, high doses, 
concurrent lithogenic drugs, and deteriorated renal function 
may represent risk factors for FBM urolithiasis [49].
Analysis of FBM-induced urinary stones showed that FBM 
and its metabolites constitute the main component of these 
stones [49–51]. FBM stones are radiolucent unless calcium 
salts are integrated in their formation, and they are charac-
terized by the presence of FBM needle-like crystals ranging 
from 90 to > 1300 μm in size. Furthermore, they have a lay-
ered or flaky appearance and are easily fragmented with hol-
mium laser lithotripsy [49, 50]. Treatment of this type of stone 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lithogenic Drugs in Pediatrics
includes reduction of FBM dose or if possible discontinuation, 
endoscopic stenting and hydration (Table 2) [49–51].
5.1.5  Silica Stones
Silica is commonly mistaken in the literature for silicate; how-
ever, they are different. Silica  (SiO2) is the oxidized form of 
silicone, and it represents the most common element of the 
earth’s crust, while silicate  (SiO4) is any tetrahydrated com-
pound of silica, and it is also a main component of the earth’s 
mantle and crusts [52]. Silica stones are extremely rare, and 
account for 0.1–0.2% of all urinary stones. They are most com-
monly documented in adult patients after long-term use of 
silica-containing antacid for treatment of peptic ulcers [53]. 
In the pediatric population, they have been associated with the 
use of silica-containing milk thickener (Gelopectose, contain-
ing 5.5% colloidal silicate) for the management of infants’ gas-
tro-esophageal reflux [54]. Only one study reported the devel-
opment of silica stones in the pediatric population (Table 2) 
[54]. Most silica stones pass spontaneously after discontinu-
ation of the drug; however, in the case of persistence, other 
treatment options are recommended (e.g., SWL or percutane-
ous nephrolithotomy) based on the stone characteristics [53].
5.1.6  Indinavir Stones
Indinavir is a strong HIV protease inhibitor that is frequently 
used together with nucleoside reverse transcriptase inhibi-
tors in the management of HIV/AIDS in adults and pediatric 
populations [55]. Indinavir is characterized by its relatively 
poor solubility at pH > 5, which can result in its precipita-
tion and crystallization [56]. Two reports in the literature 
showed urolithiasis in children infected by HIV after treat-
ment with indinavir (Table 2) [55, 56]. HIV/AIDS is a rare 
condition in the pediatric population, and this may explain 
the rarity of indinavir-induced stones in children. Indinavir-
induced stones are radiolucent on plain x-ray and computed 
tomography; on the contrary, they may be diagnosed using 
ultrasonographic imaging studies [56]. Intravenous anti-
biotics, discontinuation or replacement of indinavir, and 
hydration represent the mainstays for the management of 
these stones, as surgical intervention should be avoided, as 
it carries the risk of infection in this group of immunocom-
promised patients. Up to 83% may resolve or pass spontane-
ously [56].
5.2  Metabolically Drug‑Induced Nephrolithiasis
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5.2.1  Other Antibacterial Drugs
Overall, multiple antibacterial drugs are associated with 
renal stone formation. Considering the large number of 
patients treated with these drugs, the rarity of such a condi-
tion suggests that other favoring factors (high doses, long 
duration, low diuresis, and urine pH) may play a role [12]. 
Tasian et al. showed that several classes of antibacterial 
drugs, such as sulfas, fluoroquinolones, cephalosporins, 
nitrofurantoin, and broad spectrum penicillins, may increase 
the risk of nephrolithiasis, especially in younger populations 
[57].
Cefotaxime is also a third-generation cephalosporin simi-
lar to ceftriaxone. Ustyol et al. [38] compared the rate of 
biliary pseudolithiasis and nephrolithiasis between children 
using ceftriaxone and cefotaxime in the management of 
acute bacterial infection, showing no significant difference 
between these drugs in regard to drug-induced nephrolithi-
asis (1.2% vs 1.5%, p > 0.05). This is the only report in the 
literature about cefotaxime-induced nephrolithiasis in the 
pediatric population, and further studies are required to con-
firm the lithogenic effect of this antibacterial drug.
Furthermore, Bohles et al. [58] demonstrated that co-tri-
moxazole and ceftazidime may be associated with increased 
risk of stone formation in children suffering from cystic 
fibrosis. This may be explained by the oxalate hemosta-
sis caused by loss of the intestinal bacterium Oxalobacter 
formigenes (which is sensitive to co-trimoxazole and cef-
tazidime) causing an increased risk of hyperoxaluria and 
calcium oxalate stone formation [59]. Overall, there are 
several theories explaining the relationship between stone 
formation and different antibacterial drugs, such as the lower 
diversity of the gut microbiome in patients with nephrolithi-
asis, indicating that multiple organisms are integrated in the 
relationship between antibacterial drugs and nephrolithiasis, 
not only O. formigenes [57].
5.2.2  Furosemide
Furosemide is a loop diuretic commonly used in the pedi-
atric population for the correction of fluid overload in both 
acute and chronic disorders [60]. In the current review, 
it has been employed mainly in preterm infants with low 
birth weight or those suffering from congestive heart failure 
[61–77]. In 1982, Hufnagle et al. [66] were the first to link 
renal calcifications in preterm infants with furosemide use, 
where, over a 4-year period, they found ten preterm infants 
showing nephrolithiasis (ranging from small stones to stag-
horn calculi) within 12–44 days of high-dose furosemide 
therapy (2–4 mg/kg). Based on this finding, several authors 
studied the risk factors associated with the development of 
nephrocalcinosis and/or nephrolithiasis in preterm infants, 
showing that duration of oxygen ventilation, gestational age, 
birth weight, high calcium intake, total parenteral nutrition, 
dexamethasone, furosemide, theophylline, aminoglycosides, 
dehydration, toxic gentamycin/vancomycin levels, and male 
sex are all significant predictors in preterm infants [69–72, 
76, 78]. Furthermore, Gimpel et al. [76] found that a furo-
semide dose of > 10 mg/kg during the neonatal intensive 
care unit stay increased the risk of neonatal nephrocalcinosis 
by 48-fold. The incidence of furosemide-induced nephroc-
alcinosis in preterm infants ranges from 13.9% to 20% [75, 
77]. On the other hand, Saarela et al. [75] studied the effect 
of prolonged furosemide therapy on full-term infants with 
congestive heart failure, reporting 13.9% nephrocalcinosis 
in patients using furosemide versus 0% nephrocalcinosis 
in the control group without furosemide therapy. Interest-
ingly, Blickman et al. [73] reported the concurrent pres-
ence of nephrocalcinosis and cholelithiasis in four preterm 
infants with chronic lung disease after furosemide therapy 
for 28 days.
5.2.2.1 Pathophysiology The plasma half-life of furosem-
ide is markedly increased in preterm infants and neonates 
(33–100 min in adults vs 8–27 h in neonates). Glomerular 
filtration and tubular secretion are the main excretory path-
ways of furosemide [60]. Furosemide is capable of causing 
hypercalciuria in preterm infants through the inhibition of 
tubular calcium reabsorption [64]. In this setting, the stone 
composition in these preterm infants was available in only 
four reports (23.5%), showing calcium oxalate and/or cal-
cium phosphate stones [62, 64, 66, 74]. However, this hyper-
calciuria cannot exclusively explain the furosemide-induced 
nephrocalcinosis and/or nephrolithiasis in this age group; 
thus the mechanism of this side effect is not completely 
understood and is considered a multifactorial process [79].
5.2.2.2 Prevention and  Treatment Spontaneous resolu-
tion of nephrocalcinosis and/or nephrolithiasis occurs in up 
to 20–60% of preterm infants within 5–6 months after the 
discontinuation of furosemide [63, 70]. Discontinuation of 
furosemide therapy was the mainstay of management in the 
included studies; however, replacement with thiazide, pyel-
otomy, pyelolithotomy, and ureterolithotomy were indicated 
in some patients with persistent nephrolithiasis (Table  3) 
[61–77]. Using thiazide or potassium-sparing diuretics may 
reduce the risk of nephrocalcinosis and stone formation in 
this high-risk group, as they decrease calcium excretion [62, 
63].
5.2.3  Other Diuretics
Acetazolamide and dorzolamide are carbonic anhydrase 
inhibitors that alkalinize urine through the reduction of 
bicarbonate reabsorption [64]. They are commonly used 
as an adjunct to other drugs in the treatment of refractory 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lithogenic Drugs in Pediatrics
epilepsy [80], post-hemorrhagic hydrocephalus in preterm 
infants [64], or glaucoma [81]. These drugs are known for 
their lithogenic effects in adults [81, 82]; however, there is 
a lack of data about their effect in the pediatric population.
Stafstrom et al. [64] demonstrated that combination ther-
apy of furosemide and acetazolamide in the management of 
preterm infants with post-hemorrhagic hydrocephalus may 
be associated with an increased risk of nephrocalcinosis and/
or nephrolithiasis; thus, close monitoring of the urine cal-
cium/creatinine ratio is recommended. On the other hand, 
Katayama et al. [80] reported stone passage in a 21-year-old 
patient after 6.5 years of 10 mg/kg/day acetazolamide poly-
therapy (sodium valproate, carbamazepine, and clonazepam) 
for management of refractory epilepsy. Carlsen et al. [81] 
reported the development of renal stone in a 17-year-old 
male patient suffering from retinitis pigmentosa and perifo-
veal edema after 2 years of dorzolamide therapy (Table 3).
5.2.4  Topiramate
Topiramate (TPM) is a sulfamate-substituted derivative of 
d-fructose monosaccharide that was approved by the FDA 
in the USA in 1996 as a monotherapy or for adjunctive 
management of partial seizures, refractory epilepsy, and 
migraine prophylaxis [83]. It has even extended its indica-
tions to include some off-label uses such as mood disorders, 
obesity, and smoking cessation [84]. Thus, TPM has become 
one of the most frequently prescribed drugs in the USA, 
ranking among the top 50 most prescribed drugs [85]. TPM 
has been long known for its lithogenic effect through the 
metabolic changes induced by this drug [86–93]. A system-
atic review published in 2013 showed that the overall annual 
incidence of symptomatic nephrolithiasis with TPM usage 
was 2.1% [94]; however, the incidence of nephrolithiasis in 
the pediatric population ranged from 4.2% to 60% (Table 3). 
It is worth mentioning that the high incidence of 60% may be 
explained by the presence of other risk factors for urolithi-
asis as this study was performed in non-ambulatory children, 
a population in which there are increases in bone resorption, 
which subsequently leads to hypercalcemia and hypercal-
ciuria [86].
Two studies tried to determine the accurate incidence 
of TPM-induced urolithiasis in the pediatric population 
through comparing the incidence of urolithiasis between 
children with disability using TPM for management of 
refractory epilepsy versus a control group of similar children 
not using TPM. They showed similar results, with an inci-
dence of urolithiasis significantly higher in the TPM group 
versus the no TPM group (60% vs 0% and 54.6% vs 0%) [86, 
87]. Furthermore, an open-label extension study from two 
studies (phase 1 and phase 3) in 284 infants < 2 years old 
with refractory partial-onset seizures treated with TPM (only 
135 infants completed the open-label extension study) was 
published in 2011 and showed that one of the treatment-
emergent adverse events found was nephrolithiasis in 18 of 
the 135 patients (13.3%) [93].
5.2.4.1 Pathophysiology TPM has several mechanisms of 
action, including weak carbonic anhydrase inhibition (simi-
lar to acetazolamide) that increases bicarbonate excretion 
by the proximal tubules. Moreover, it leads to an increase 
in calcium excretion and citrate reabsorption. Interestingly, 
TPM may cause an increase in bicarbonate loss through the 
gastrointestinal tract (mostly due to diarrhea). These meta-
bolic alterations cause metabolic acidosis, elevated urinary 
pH, hypocitraturia, and hypercalciuria and, subsequently, 
an increase in the risk of calcium stone formation [83, 86]. 
Dell’Orto et al. [94] demonstrated in their systematic review 
a significant tendency towards metabolic acidosis, where 
the circulating bicarbonate was significantly lower in TPM 
patients compared to control subjects; however, this find-
ing was not significantly related to the dose of TPM. In this 
review, few studies reported the urinary pH and the calcium/
creatinine ratio, and these ranged from 6.8–8.07 [86, 87] 
and 0.22–0.30 [87, 89], respectively. Generally, the relation 
between TPM administration and stone formation should 
be interpreted with caution, as stone composition was not 
analyzed in most of the patients reported in the literature 
and the causal relationship was based only on the duration 
between the stone event and the start of medication.
5.2.4.2 Prevention and Treatment Barnett et  al. [92] rec-
ommended that all children undergoing TPM therapy should 
have a baseline evaluation including urinalysis, urinary cal-
cium/creatinine ratio, serum electrolyte and urinary citrate/
creatinine ratio, with follow-up of these tests at 6-month 
intervals. Furthermore, children who show a urine calcium/
creatinine ratio > 0.21 should have renal ultrasonography 
follow-up every 6  months. Potassium citrate may also be 
used while on TPM therapy to reduce the risk of urolithi-
asis. The included studies showed that discontinuation 
may be difficult in some children; thus the main treatment 
options were endoscopic lithotripsy, SWL, and open surger-
ies (Table 3).
5.2.5  Zonisamide
Zonisamide (ZNS) is a carbonic anhydrase inhibitor similar 
to TPM; however, it is reported to be 100 times less potent 
as a carbonic anhydrase II inhibitor than acetazolamide 
[95]. It has been strongly associated with urolithiasis and 
crystalluria in the pediatric population (Table 3) [95–99]. 
Go [98] studied the metabolic effect of ZNS through exam-
ining the urine of 27 children 1 month after starting ZNS 
therapy and 1 month after its withdrawal, demonstrating 
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that urinary pH was not significantly changed with the 
addition or the withdrawal of ZNS; however, the degree of 
crystalluria was significantly increased after addition and 
significantly decreased after the withdrawal of ZNS therapy. 
Furthermore, Go [97] showed in another study that crystal-
luria during ZNS therapy was increased with the number 
of antiepileptic drugs used, where crystalluria was found in 
31%, 53.3%, and 45.5% of 278 urine samples obtained from 
patients treated with two, three, and more than three drugs, 
respectively. Wroe [100] used the reports of four placebo-
controlled, double-blind trials on ZNS treatment to identify 
the actual incidence of ZNS-induced urolithiasis among 
patients treated for epilepsy. At 3 months of ZNS, there was 
no symptomatic nephrolithiasis among the 498 patients on 
ZNS therapy; however, a follow-up at 24 months (open-label 
extension study) showed renal calculi in nine out of 626 
patients (1.4%). Furthermore, the “all zonisamide” popula-
tion database, that is a database including all the patients 
included in USA and European clinical trials, showed an 
incidence of 15 out of 1296 (1.2%) at 8.7 years follow-up 
[100].
5.2.5.1 Pathophysiology The pathophysiology of ZNS-
induced urolithiasis is similar to that of TPM, where it blocks 
normal bicarbonate reabsorption, resulting in primary alka-
linization of urine and acidification of blood, followed by 
urine acidification as well. Furthermore, it provokes hyper-
calciuria through increases in sodium and calcium excretion. 
Eventually, the kidney tries to compensate for the resulting 
metabolic acidosis through the reabsorption of citrate, caus-
ing a further increase in the risk of urolithiasis [101]. Only 
one study reported analysis of ZNS-induced stones, show-
ing that they are composed mainly of calcium oxalate and 
calcium phosphate [95].
5.2.5.2 Prevention and  Treatment Most of the studies 
about ZNS-induced urolithiasis in children showed that 
hydration and discontinuation of ZNS are sufficient treat-
ment for the developed crystalluria, urolithiasis and urinary 
bladder sludges [95, 99].
5.2.6  Ketogenic Diet
Despite not being a medication, we decided to add the 
ketogenic diet in this review as it is a major risk factor for 
nephrolithiasis in pediatric patients treated with antiepileptic 
drugs such as TPM and ZNS. The ketogenic diet is a high-
fat, low-carbohydrate, and adequate-protein diet that has 
been used in the management of refractory epilepsy since 
1921 [101]. This diet carries an increased risk of nephro-
lithiasis (3–10%) in pediatric patients treated for refractory 
epilepsy [102]. The ketogenic diet provokes urolithiasis 
through multiple mechanisms, including hypercalciuria, 
hypocitraturia, chronic acidosis, and dehydration. The met-
abolic acidosis resulting from the ketogenic diet increases 
the calcium excretion through reducing calcium reabsorp-
tion and increasing bone demineralization. Furthermore, 
this acidosis and metabolic changes may lower the urinary 
pH, reducing the uric acid solubility. Interestingly, the 
most important factor is dehydration, as the ketogenic diet 
interferes with the normal thirst mechanism. All these fac-
tors play an important role in the lithogenic effect of the 
ketogenic diet in children with refractory epilepsy [102, 
103].
Paul et al. [101] compared three groups of children suffer-
ing from epilepsy, where 47 children who were treated only 
with ketogenic diet did not show any nephrolithiasis. On the 
other hand, nephrolithiasis was reported in 17.6% and 4.5% 
of children treated with the ketogenic diet + TPM and the 
ketogenic diet + ZNS, respectively. On the contrary, Kossoff 
et al. [104] reported no difference as regards the incidence 
of urolithiasis between epileptic children treated with the 
ketogenic diet alone and those treated with the ketogenic 
diet + ZNS or TPM (6.8% vs 6.3%, respectively). Hydration 
and alkalinization of urine represent the main preventive 
measures and treatment options for ketogenic diet–induced 
urinary stones [101–104]. Importantly, the ketogenic diet 
is associated with bleeding tendency in approximately one 
third of children treated for epilepsy. This may be explained 
by the presence of underlying bleeding-susceptibility factors 
together with the decreased platelet responsiveness induced 
by the ketogenic diet (due to changes in the lipid compo-
sition of the platelet membrane) [105]. This is clinically 
important, especially if children require extracorporal SWL 
for management of their stones. Table 3 shows a summary 
of the studies discussing antiepileptic drugs and urolithiasis.
5.2.7  Allopurinol
Allopurinol is a xanthine oxidase inhibitor that is commonly 
used in the treatment of gout, to control the hyperuricemia 
occurring as a part of Lesch-Nyhan syndrome (LNS), and to 
prevent tumor lysis syndrome in patients with acute lympho-
blastic leukemia (ALL) before the induction of chemother-
apy [106, 107]. Several reports demonstrated that allopurinol 
is associated with an increased risk of xanthine urolithiasis 
in children [106–115]. Table 3 summarizes all the reports of 
allopurinol-induced urolithiasis in the pediatric population 
discussed in the current review.
However, the incidence of urolithiasis in ALL patients 
is extremely rare; its incidence is increased during chem-
otherapy. Several factors may contribute to the increased 
risk, including glucocorticoid therapy, which may increase 
the risk of urolithiasis up to 48-fold during induction and 
22-fold during continuation therapy [116]. Furthermore, 
ALL chemotherapy may be associated with hyperuricemia 
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and tumor lysis syndrome, which may increase the risk of 
urolithiasis in these patients [106]. Three case reports in 
the literature demonstrated the occurrence of urolithiasis in 
two 11-year-old boys and one girl taking allopurinol dur-
ing the induction of chemotherapy for the management of 
ALL [106, 110, 115]. In one boy, the stone passed following 
treatment by forced hydration, and on analysis, it showed 
calcium phosphate composition [106]. The other boy and 
the girl died, and the autopsy analysis of the stones showed 
xanthine composition [110, 115].
LNS describes the presence of the triad consisting of 
hyperuricemia, central nervous system disorder, and famil-
ial inheritance, and it is characterized by a low incidence 
ranging from 1:100,000 to 1:300,000. The hyperuricemic 
component of this syndrome increases the risk of urolithiasis 
and gout [107]. Torres et al. [114] reported 15.8% urolithi-
asis after allopurinol therapy in children with LNS. Further-
more, several authors demonstrated that allopurinol therapy 
in children suffering from LNS was associated with multiple 
large stones [107–109, 113]. On the contrary, Greene et al. 
[112] reported the development of multiple small stones in 
a 16-year-old boy with LNS after allopurinol therapy.
5.2.7.1 Pathophysiology Allopurinol reduces uric acid pro-
duction through inhibition of the xanthine oxidase enzyme, 
which is responsible for the conversion of xanthine to uric 
acid. In this setting, it increases the excretion of xanthine in 
urine. Xanthine is characterized by its low urine solubility; 
thus it may precipitate and increase the risk of urolithiasis 
[107, 110]. Moreover, the significant increase in the urinary 
level of oxypurinol, which is a metabolite of allopurinol, 
may predispose patients to the process of urolithiasis [107].
Allopurinol-induced urinary stones are usually composed 
of xanthine with/without oxypurinol [107–115]. Xanthine 
stones are typically radiolucent with Hounsfield units similar 
to the uric acid stones on computed tomography, and they 
occur more commonly in the upper urinary tract [108].
5.2.7.2 Prevention and  Treatment Aggressive hydration, 
alkalinization, and adjustment of the allopurinol dosage 
represent the corner stone for the management of xanthine 
stones [108]. Potassium citrate may be used for urine alka-
linization [109]; however, urinary pH should be carefully 
monitored during allopurinol therapy, as its increase above 
7.0 increases the risk for calcium phosphate stone formation 
[108]. The allopurinol dosage should be strictly adjusted 
not to exceed 5 mg/kg/day in children and 100 mg/day in 
adults to allow the reduction of serum uric acid production 
without overproduction of xanthine, thus reducing the risk 
of urolithiasis [107]. If these measures fail, other treatment 
options may be used, including SWL, percutaneous nephro-
lithotomy, endoscopy and open surgery [106–115].
5.2.8  Vitamins
There are scarce data about the association between vitamin 
supplements and stone formation in the pediatric population. 
Urolithiasis was reported in one child who had a long his-
tory of vitamin C supplementation [117] and another child 
who had a 1-month history of vitamin D supplementation 
[118]. It is worth mentioning that the common risk factor 
between the two case reports was the very high dose con-
sumption of vitamin supplements that led to vitamin intoxi-
cation (Table 3).
5.2.9  Others
Pozzi et al. [119] compared 191 pediatric patients who were 
capable of oral feeding versus 180 children who were on 
enteral nutrition to assess the incidence of urolithiasis among 
both groups. Interestingly, the oral feeding group showed no 
stones, while the enteral nutrition patients showed urolithi-
asis: 26 (14.4%); thus, the authors concluded that the use 
of enteral nutrition was significantly associated with stone 
formation (p < 0.001).
Moreover, methotrexate and prednisone are part of the 
chemotherapy used in different cancers. Some authors sug-
gested that these drugs may increase the risk of stone for-
mation in patients with ALL and kidney transplant patients 
[120, 121]. Dexamethasone and aminoglycosides have also 
been associated with increased risk of nephrocalcinosis in 
low-birth-weight infants [122].
6  Conclusion
Despite drug-induced nephrolithiasis being uncommon, 
it should be considered by physicians when dealing with 
children suffering from urinary tract calculi; otherwise an 
accurate diagnosis and the underlying cause will be missed, 
which may have harmful consequences. Careful evaluation 
with a detailed medical history including associated comor-
bidities and history of drug consumption is paramount for 
the diagnosis and management of this condition. Adequate 
knowledge of the potentially lithogenic drugs and follow-up 
of children receiving these drugs for a long duration, espe-
cially those with risk factors or a positive family history, can 
reduce the incidence of drug-induced urolithiasis.
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